FGFR-2 and Epithelial–Mesenchymal Transition in Endometrial Cancer

Abstract

Background. At present, EC staging is based on the WHO conservative criteria, which only consider the percentage of gland formation. The molecular subgrouping of EC recently proposed by the Cancer Genome Atlas (TCGA) represents a milestone in precise molecular-based patient triage. The present study aimed to investigate the influence of FGFR-2 on the epithelial–mesenchymal transition (EMT) and whether it can lead to endometrial cancer dedifferentiation. Methods. One hundred and three White female patients with confirmed EC were enrolled in our research. For the analysis, we performed next-generation sequencing and immunohistochemical analyses of E-cadherin, β-catenin, and vimentin. Results. Tumor grade progression was closely correlated with LVI (p = 0.0338), expression of vimentin (p = 0.000), tumor budding (p = 0.000), and lack of E-cadherin (p = 0.0028). Similar observations were noted with regard to TNM/FIGO stage progression. In terms of FGFR-2 mutation, we found the following correlation p-values: LVI (p = 0.069), expression of vimentin (p = 0.000), tumor budding (p = 0.000), and lack of E-cadherin (p = 0.000), RFS (p = 0.032), ECSS (p = 0.047). Conclusions. FGFR-2 is the important factor influencing on EMT.

Expression and Clinicopathological Relevance of Fibroblast Growth Factor Receptors in Canine Mammary Gland Tumors

“…Although this study did not find significant association between FGFRs and Vimentin expressions, the leading role of FGFRs in the activation of epithelial-mesenchymal transition (EMT) in mouse mammary tumor virus-Neu epithelium (Qian et al 2004) and human breast cancer, with Vimentin expression been associated with FGFR1 expression in human breast cancer, have been documented (Cheng et al 2013). Moreover, FGFR2 expression is also reported to be associated with EMT in endometrial cancer (Adamczyk-Gruszka et al 2022). Beside their roles in EMT, the roles of FGFRs signalling extend to the next step in the establishment of metastasis, which is mesenchymal epithelial transition (MET).…”

Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients

“…As recently shown by Adamczyk-Gruszka et al, not only molecular subgrouping but also distinct mutations might influence the cancer cell-stroma interaction, and therewith the morphologic features. In their recent publication, the impact of FGFR2 mutations on EMT (and TB as one of the EMT hallmarks) was described [52]. Furthermore, e.g., aberrant ß-catenin expression was strongly correlated with TB (reviewed by [18]).…”

Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors

“…The role of IDO-1 in EC was already mentioned. Fibroblast growth factor receptor (FGFR) plays a role in angiogenesis, and FGFR2 mutations found in around 15% of EC leads to FGFR overexpression and favors the proliferation of tumor cells and metastasis [ 102 , 103 ]. Shorter disease-free survival and OS are observed in these patients, especially at an early stage, owing to the lack of treatment options.…”